Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

49.54 +0.64 (+1.31%)
Streaming Delayed Price Updated: 10:26 AM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
39 40 Next >
News headline image
Why Regeneron Pharmaceuticals Shares Are Trading Lower Today ↗
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned adjusted EPS of $10.09, down 12% Y/Y, beating  
Via Benzinga
News headline image
7 Stock Upgrades and Downgrades Alerts You Cannot Ignore ↗
Analyst stock upgrades and downgrades caught the market's attention in the last week and putting investors on notice for buys and sells. 
Via InvestorPlace
News headline image
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
European Union's Amended COVID-19 Vaccine Deal with Pfizer-BioNTech: Near-Monopoly Status Potential Threat to Rivals ↗
The European Union bloc is reportedly negotiating an amended deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for around 70 million COVID-19 vaccine doses, despite the European public... 
Via Benzinga
News headline image
Sanofi (SNY) Q1 2023 Earnings Call Transcript ↗
SNY earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Sanofi (NASDAQ: SNY) Records 52-Week High Wednesday Morning
Via Investor Brand Network
News headline image
Earnings Outlook For Sanofi ↗
 
Via Benzinga
News headline image
Sanofi In-Licenses Pompe Disease Therapy From Privately-Held Maze Therapeutics For $150M Upfront ↗
Maze Therapeutics has signed an exclusive worldwide license agreement with Sanofi SA (NASDAQ: SNY) for Maze's glycogen synthase 1 (GYS1) program, including clinical candidate MZE001, which is currently... 
Via Benzinga
News headline image
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks? ↗
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
News headline image
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales ↗
French drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in  
Via Benzinga
News headline image
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet' ↗
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher. 
Via Benzinga
Sanofi (NASDAQ: SNY) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Sanofi (NASDAQ: SNY) Climbs to New 52-Week High
Via Investor Brand Network
News headline image
Earnings Scheduled For April 27, 2023 ↗
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter. 
Via Benzinga
News headline image
AbbVie Stock Shows Improved Relative Price Strength ↗
AbbVie stock had its Relative Strength Rating upgraded from 69 to 76 Thursday, but still shy of the 80 or higher score you prefer to see. 
Via Investor's Business Daily
News headline image
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz ↗
 
Via Benzinga
News headline image
United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review ↗
The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003. 
Via Benzinga
News headline image
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... 
Via Benzinga
News headline image
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So ↗
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
News headline image
3 Healthcare Dividend Payers With Big Price Growth
Sanofi, AstraZeneca and Smith & Nephew all boast price performance better than about 80% of the broader market, and all are dividend payers. 
Via MarketBeat
News headline image
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise ↗
Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies... 
Via Benzinga
News headline image
Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information ↗
 
Via Benzinga
News headline image
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow ↗
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global... 
Via Benzinga
News headline image
Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens ↗
Zoetis stock is trying to complete a flat base with a 176.76 buy point. See if it can break out. Its stock got an upgrade Monday 
Via Investor's Business Daily
News headline image
2 Top Healthcare Stocks Defying the Bear Market ↗
The market sell-off over the past year hasn't stopped these healthcare giants from rallying. 
Via The Motley Fool
News headline image
Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market ↗
Its market dominance in diabetes drugs that also help with weight loss is set to continue for at least the next few years. 
Via The Motley Fool
News headline image
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity? ↗
Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease. 
Via The Motley Fool
News headline image
Zoetis Stock Sees IBD Relative Strength Rating Improve To 73 ↗
Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for. 
Via Investor's Business Daily
News headline image
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade. 
Via MarketBeat
News headline image
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock? ↗
Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication. 
Via The Motley Fool
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.